Breaking News Instant updates and real-time market news.

CMG

Chipotle

$404.14

-5.67 (-1.38%)

, VRX

Valeant

$22.18

-0.59 (-2.59%)

08:51
10/17/16
10/17
08:51
10/17/16
08:51

Ackman has 'hands full' with Chipotle, Vanity Fair's Cohan says

In a piece questioning if Pershing Square's Bill Ackman has a "comeback left in him," William Cohan of Vanity Fair says that the investor has his "hands full" with Chipotle Mexican Grill (CMG). Chipotle remains an expensive stock at over 60 times its earnings, and complaints about its food quality persist, Cohan writes. Hedge-fund manager and Ackman antagonist John Hempton told Cohan, "If Valeant does what I think it's going to do, which is eventually file bankruptcy, and Herbalife does what I think it's going to do, the position will be very unsurvivable. He's not very good at consumer, and I'm wondering why he's gone into Chipotle as his latest." Reference Link

CMG

Chipotle

$404.14

-5.67 (-1.38%)

VRX

Valeant

$22.18

-0.59 (-2.59%)

HLF

Herbalife

$61.61

-0.82 (-1.31%)

  • 25

    Oct

  • 01

    Nov

  • 16

    Nov

  • 14

    Dec

CMG Chipotle
$404.14

-5.67 (-1.38%)

09/14/16
JPMS
09/14/16
NO CHANGE
JPMS
JPMorgan says buy three restaurant stocks after recent weakness
JPMorgan analyst John Ivankoe recommends using recent volatility to buy McDonald's (MCD), Starbucks (SBUX) and Yum! Brands (YUM), but not Chipotle Mexican Grill (CMG). On Chipotle, the analyst recommends using meaningful price weakness, closer to or below $400, to accumulate the shares.
09/21/16
GSCO
09/21/16
NO CHANGE
Target $395
GSCO
Neutral
Chipotle comp outlook lowered on slowing Chiptopia benefit at Goldman
Goldman analyst Karen Holthouse said Chiptopia search trends continue to show a significant drop-off in August. As a result, the analyst lowered Q4 comp estimate to down 21.4% from down 18.4% and versus consensus of down 17.7%. Holthouse also trimmed forward estimates and now forecasts Q4 comp of down 5%. The analyst rates Chipotle a Neutral and lowered its price target to $395 from $445.
10/07/16
WBLR
10/07/16
NO CHANGE
WBLR
Outperform
William Blair survey shows modest Chipotle sentiment improvement
William Blair analyst Sharon Zackfia says her firm's latest survey of 800 adults showed "modest improvement" in food safety concerns relating to Chipotle Mexican Grill. The percent of respondents "not worried at all" or "not very worried" about food safety hit a survey high of 60%, while the percent of "very worried" respondents stabilized in the 12% to 14% range since June, Zackfia tells investors in a research note. The analyst, however, points out that the percent of respondents eating less frequently at Chipotle remains "persistently high" at 45%, essentially showing no real sustainable improvement since April. Zackfia expects Chipotle's comp sales to stay "significantly negative" through October. The analyst keeps an Outperform rating on the shares.
10/11/16
10/11/16
NO CHANGE

Chipotle checks remain weak, says M Science
VRX Valeant
$22.18

-0.59 (-2.59%)

09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.
10/14/16
WELS
10/14/16
NO CHANGE
WELS
Underperform
Wells says Valeant price hikes a reaction to 'disappointing' prescription trends
Wells Fargo analyst David Maris noted Valeant's announcement earlier today that the company has decided to raise prices by 2% to 9% on a broad range of products. He believes the price increases are a result of the company taking "a sobering look at disappointing prescription trends" and continues to contend that consensus estimates for Valeant in 2017 are too high. The analyst, who has kept an Underperform rating on Valeant shares since starting coverage of the stock in February, said the company's "story is the same as it has been, and the only change is in how it is being told."
HLF Herbalife
$61.61

-0.82 (-1.31%)

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

11:17
01/22/18
01/22
11:17
01/22/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.66

0.59 (0.65%)

11:16
01/22/18
01/22
11:16
01/22/18
11:16
Technical Analysis
Technical Earnings Preview: Procter & Gamble near life highs before news »

The stock is not far from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

$NYE

NYSE Market Internals

11:16
01/22/18
01/22
11:16
01/22/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$55.80

0.63 (1.14%)

11:15
01/22/18
01/22
11:15
01/22/18
11:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Treasury announced a $35 B 4-week bill offering for Tuesday »

Treasury announced a $35…

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

LQ

La Quinta

$20.32

0.135 (0.67%)

, WYN

Wyndham

$126.65

-0.34 (-0.27%)

11:13
01/22/18
01/22
11:13
01/22/18
11:13
Downgrade
La Quinta, Wyndham rating change  »

La Quinta downgraded to…

LQ

La Quinta

$20.32

0.135 (0.67%)

WYN

Wyndham

$126.65

-0.34 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

11:10
01/22/18
01/22
11:10
01/22/18
11:10
Periodicals
KGI's Kuo says Apple will discontinue first-generation iPhone X, MacRumors says »

Apple will discontinue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

11:04
01/22/18
01/22
11:04
01/22/18
11:04
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

ZIOP

Ziopharm

$4.28

-0.08 (-1.83%)

11:02
01/22/18
01/22
11:02
01/22/18
11:02
Periodicals
Ziopharm rise due to 'stupid money' inflow, Feuerstein says »

Adam Feuerstein tweeted:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$20.35

0.17 (0.84%)

11:02
01/22/18
01/22
11:02
01/22/18
11:02
Downgrade
La Quinta rating change  »

La Quinta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBI

Northwest Bancshares

$17.09

0.24 (1.42%)

11:01
01/22/18
01/22
11:01
01/22/18
11:01
Earnings
Northwest Bancshares reports Q4 EPS 22c, consensus 22c »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.10

-0.34 (-5.28%)

11:01
01/22/18
01/22
11:01
01/22/18
11:01
Hot Stocks
AK Steel: Ladle at Middletown Works caster malfunctioned, no injuries reported »

AK Steel said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

XLU

Utilities SPDR

$50.47

0.48 (0.96%)

11:00
01/22/18
01/22
11:00
01/22/18
11:00
Options
Renewed interest in SPDR Utility Fund Mar 49 puts »

Renewed interest in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBI

Northwest Bancshares

$17.09

0.24 (1.42%)

10:59
01/22/18
01/22
10:59
01/22/18
10:59
Hot Stocks
Northwest Bancshares boosts quarterly dividend 6.25% to 17c per share »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$11.61

0.4715 (4.23%)

10:56
01/22/18
01/22
10:56
01/22/18
10:56
Hot Stocks
Barclays: Nehren as head of statistical modeling & development, Equities »

Barclays announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$269.46

-1.24 (-0.46%)

10:55
01/22/18
01/22
10:55
01/22/18
10:55
Options
Align Technology put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HPQ

HP Inc.

$23.78

0.075 (0.32%)

10:55
01/22/18
01/22
10:55
01/22/18
10:55
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DXCM

Dexcom

$56.05

-0.23 (-0.41%)

, MDT

Medtronic

$85.75

-0.93 (-1.07%)

10:54
01/22/18
01/22
10:54
01/22/18
10:54
Conference/Events
Piper Jaffray medical technology analyst holds analyst/industry conference call »

Medical Technology…

DXCM

Dexcom

$56.05

-0.23 (-0.41%)

MDT

Medtronic

$85.75

-0.93 (-1.07%)

PODD

Insulet

$75.18

2.29 (3.14%)

TNDM

TNDM

ABT

Abbott

$59.07

-0.24 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

IBCP

Independent Bank

$23.85

0.25 (1.06%)

10:46
01/22/18
01/22
10:46
01/22/18
10:46
Hot Stocks
Independent Bank raises quarterly cash dividend 25% to 15c per share »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

FCAU

Fiat Chrysler

$24.07

0.14 (0.59%)

10:45
01/22/18
01/22
10:45
01/22/18
10:45
Options
Fiat Chrysler call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
01/22/18
01/22
10:45
01/22/18
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

TEVA

Teva

$20.77

0.07 (0.34%)

10:44
01/22/18
01/22
10:44
01/22/18
10:44
Recommendations
Teva analyst commentary  »

Teva failed study removes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$39.10

0.15 (0.39%)

10:40
01/22/18
01/22
10:40
01/22/18
10:40
Hot Stocks
New Jersey Resources says FERC approves PennEast pipeline »

New Jersey Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 08

    Feb

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.